End-July 2019, a case of tick-borne encephalitis (TBE) in a 3-month-old infant was notified to the German mandatory surveillance system for infectious diseases. The patient's family, resident in a TBE-non-endemic region in Germany, had holidayed in England during the incubation time. We present the case report based on German surveillance data, information provided by the family, laboratory reports and two hospital discharge summaries, and describe the public health response.

Case report
===========

A German family including a 3-month-old infant spent their holiday in southern England from 1 to 15 July 2019 ([Figure 1](#f1){ref-type="fig"}). The mother was not vaccinated against nor reported past TBE infection. On 6 July, the family picnicked near Woodgreen in the New Forest National Park ([Figure 2](#f2){ref-type="fig"}), where the child laid on a blanket on the grass. An unengorged tick, attached to the infant's neck, was discovered on 7 July. The tick was removed incompletely, using tweezers, and the wound was disinfected. The remaining tick fragments detached 2 days later.
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The previously healthy infant developed fever on 17 July, 11 days after the tick bite. Medical history was unremarkable; the infant had thus far received one hexavalent routine childhood vaccination. Subtracting the maximum incubation period of 28 days \[[@r1]\] from symptom onset, renders 19 June as the earliest possible infection date. The infant reportedly did not visit any other location where a tick bite could have occurred except their home area in Hesse, Germany which is non-endemic for TBE. Each bout of fever was accompanied by focal seizures, lasting ca 1 min. Hospitalisation occurred on 17 July, prompting a series of diagnostic tests ([Table](#t1){ref-type="table"}). Based on elevated cerebrospinal fluid markers ([Table](#t1){ref-type="table"}), meningitis was diagnosed and the infant was treated with intravenous cefotaxime, ampicillin and aciclovir. The focal seizures became generalised lasting up to 5 min and were treated with anticonvulsants (clonazepam, midazolam, levetiracetam). The infant was transferred to a specialised hospital on 20 July. Magnetic resonance imaging and repeated electroencephalograms revealed pathological results ([Table](#t1){ref-type="table"}). Having excluded numerous neurotropic pathogens, TBEV-specific serology tested positive for IgM and IgG ([Table](#t1){ref-type="table"}) and meningoencephalitis because of TBEV infection was diagnosed by the treating physicians. The infant was discharged 15 days after admission with mild remaining neurological symptoms, which had subsided by the check-up 6 weeks later.

###### Diagnostic tests performed on the probable case of tick-borne encephalitis (TBE) during hospitalisation, Germany, July--August 2019

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------
  Date (2019)         Test (sample type/assay)             Result                                                                   Interpretation
  ------------------- ------------------------------------ ------------------------------------------------------------------------ -------------------------------
  17--19 Jul^a^       CSF diagnostics                      1,000 cells (norm: 0--5)\                                                Inflammation
                                                           (40% granulocytes, 60% lymphocytes)\                                     
                                                           1.5 g protein\                                                           
                                                           59 mg/dL glucose level (norm: 40--80)                                    

  17--19 Jul^a^       Blood culture                        Negative                                                                 Normal

  17--19 Jul^a^       CSF culture                          Negative                                                                 Normal

  17--19 Jul^a^       Multiplex PCR (CSF) for:\            Negative                                                                 Normal
                      -*Escherichia coli*,\                                                                                         
                      -*Haemophilus influenzae*,\                                                                                   
                      -*Listeria monocytogenes*,\                                                                                   
                      -*Neisseria meningitidis*,\                                                                                   
                      -Streptococcus,\                                                                                              
                      -Cytomegalovirus,\                                                                                            
                      -Enterovirus,\                                                                                                
                      -Herpes Simplex Virus 1 and 2,\                                                                               
                      -Human herpesvirus 6,\                                                                                        
                      -Human parechovirus,\                                                                                         
                      -Varicella zoster virus,\                                                                                     
                      -Cryptococcus                                                                                                 

  17--19 Jul^a^       Enterovirus (stool)                  Negative                                                                 Normal

  20 Jul              MRSA and MRGN screening              Negative                                                                 Normal

  23 Jul              TBEV-IgG (serum)^b^                  10.3 AE/mL                                                               Positive (cut-off: 0.241)

  23 Jul              TBEV-IgM (serum)^b^                  12.5 index                                                               Positive (cut-off: 0.234)

  25 Jul              *Borrelia burgdorferi* (IgG-ELISA)   \< 5.2 U/mL                                                              Negative (cut-off: \< 7 U/mL)

  22 Jul and 25 Jul   Electroencephalography               Slowed activity in right hemisphere;\                                    Pathological
                                                           Epileptic activity in right temporal/central and left occipital areas.   

  01 Aug              Magnetic resonance imaging           Leptomeningeal enhancement.\                                             Pathological
                                                           No sign of parenchymal defect or brain abscess.                          
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------

CSF: cerebrospinal fluid; MDRGN: multidrug resistant Gram-negative bacteria; MRSA: methicillin-resistant *Staphylococcus aureus*; TBEV: tick-borne encephalitis virus.

^a^ Performed during the first hospital stay. Exact test dates were not given in discharge summary.

^b^ The test kit used was Enzygnost Anti-TBE virus (IgG, IgM) (Siemens, Marburg, Germany) which determines a specific cut-off for each run (alpha-method).

Public health response
======================

Upon receiving the notification on 25 July, the Robert Koch Institute asked the patient's family for their detailed travel history in England. One week later, the event was reported through the European Commission Early Warning and Response System (EWRS) selective exchange to inform United Kingdom (UK) colleagues.

Following TBEV detection in ticks in Thetford Forest in 2019, from samples collected February 2018 to January 2019 \[[@r2]\], enhanced clinical surveillance activities were underway in the east of England, focusing on encephalitis cases without confirmed cause \[[@r3]\]. Following the EWRS message, these activities were extended to areas surrounding the New Forest National Park. TBEV seroprevalence studies in groups at high risk of tick bites and in the general population are also being implemented in both areas. Tick surveillance was already underway around the New Forest National Park following previous findings \[[@r2]\], but additional tick surveys were conducted around Woodgreen on 8 and 23 August 2019. Only 135 ticks (70 nymphs, 25 adult males, 40 adult females) were collected, likely because the peak tick questing season had already passed. Pools of 10 nymphs, five adult males or five adult females were homogenised for RNA extraction and RT-PCR analysis \[[@r4]\]. No TBEV or other TBEV-serocomplex RNA was detected.

Discussion
==========

We report a human TBE case, believed to be the first acquired in the UK. Diagnosis was by serology only, which can be regarded as a limitation. No reserve sample was available for additional testing (TBE-specific PCR or neutralization assay \[[@r5]\]). Because of the lack of therapeutic consequences, no follow-up blood sample was drawn from the infant; therefore it was not possible to test for a rise in IgG titre in paired samples \[[@r5]\].

Several pieces of evidence support the likelihood that this is a true TBE case. First, the tick bite, the clinical symptoms and the incubation time of 11 days, close to the median of 8 days \[[@r5]\], fit the typical picture of TBEV-infection. This patient did not have the biphasic course of TBE, which is observed in 72--87% of TBE cases \[[@r5]\]. Second, as the infant resides in a TBE-non-endemic area in Germany it is highly unlikely that a second tick bite occurred there within the incubation time, went unnoticed and caused the infection. The likelihood of the infection having occurred near Woodgreen is far higher given the known tick bite. Third, the extensive array of differential diagnostics ruled out numerous other neurotrophic pathogens. Fourth, the TBE serological results were far above the cut-offs. Finally, as the mother did not report any past TBE vaccination or infection, it is unlikely that maternal TBE antibody transfer occurred, and certainly not with such high titres.

In 2019, TBEV was reported for the first time in ticks in discrete foci in Thetford Forest, England \[[@r2]\], but the pathogenicity is unknown and no other human cases have yet been identified in the UK. Tick surveys around Woodgreen did not detect any TBEV, however, it must be noted that only a small tick sample was collected. Yet, a pool of questing ticks sampled previously, on the Hampshire/Dorset border in June 2019, tested TBEV-positive, suggesting that TBEV has established itself in the UK \[[@r6]\]. Follow-up tick surveys will be conducted during spring 2020.

Although the clinical presentation and serology are consistent with the European TBE case definition \[[@r7]\], this interpretation has to be considered in light of the natural endemicity of Louping ill virus (LIV) in the UK. Until recently, LIV was believed to be the only virus of the TBE-serocomplex endemic in the UK \[[@r8]\]. Like TBEV, LIV is also transmitted by *Ixodes ricinus* ticks and mainly occurs in sheep, cattle and red grouse in upland grazing areas of the British Isles \[[@r8]\]. LIV infects humans in rare cases and cross-reacts with TBEV serologically. In the absence of an isolate or sequence data from acute phase samples, the exact aetiology in the case presented here remains uncertain. However, LIV is most prevalent in upland areas, which are located mostly in the north and west of the UK, and less than 50 human clinical LIV cases have been reported since 1934 \[[@r8]\], with one in England reported as recently as 2011 \[[@r9]\]. The likelihood of LIV thus is low in our case and we believe that it is a true TBEV-infection.

This first probable human TBEV-infection in England and the detection of TBEV in ticks stand in accordance with the patchy spread of TBEV to new areas observed in parts of Europe. In Germany, the number of TBE-endemic districts increased from 129 in 2007 to 161 in 2019 \[[@r10]\]. The first TBE cases from the Netherlands were reported in 2016 \[[@r11],[@r12]\]; and a new focus was recently discovered in Denmark following three human TBE cases in summer 2019 \[[@r13]\]. TBEV can spread to new areas through mammalian hosts or migratory birds infested with TBEV-carrying ticks \[[@r14]\]. This may either lead to sporadic infections, or sometimes to the establishment of new foci, if local climatic conditions are favourable to the transmission cycles between ticks and their rodent hosts \[[@r5]\].

In England, the public health authorities currently assess the risk of TBEV infection as very low for the general population and low for those who may be bitten by ticks in areas where infected ticks are located \[[@r15]\]. Seroprevalence studies in groups at high risk of tick bites and in the general population, tick sampling and enhanced surveillance of human encephalitis cases without confirmed cause are underway to better understand the human infection risk in areas where TBEV was detected in ticks or wildlife. Public Health England continues to promote tick awareness for those spending time outdoors. The public health risks from TBEV in England will be dynamically reviewed as new findings come to light.
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